Skip to main content

Medications for Acute Myeloid Leukemia

Other names: Acute Granulocytic Leukemia; Acute Myelogenous Leukemia; AML; Cancer, Acute Granulocytic Leukemia; Cancer, Acute Myelogenous Leukemia; Cancer, Acute Myeloid Leukemia; Leukemia, Acute Granulocytic; Leukemia, Acute Myelogenous; Leukemia, Acute Myeloid

Acute myeloid leukemia (AML) is cancer that starts inside bone marrow, the soft tissue inside bones that helps form blood cells. The cancer grows from cells that would normally turn into white blood cells.

Drugs used to treat Acute Myeloid Leukemia

The medications listed below are related to or used in the treatment of this condition.

Drug name Rating Reviews Activity ? Rx/OTC Pregnancy CSA Alcohol
Komzifti
New approval
Rate Add review Rx U
Generic name:
ziftomenib systemic
For consumers:
For professionals:
Prescribing Information
FDA approval date:
November 13, 2025
Revuforj
New approval
Rate Add review Rx N
Generic name:
revumenib systemic
Drug class:
miscellaneous antineoplastics
For consumers:
dosage, interactions, side effects
For professionals:
Prescribing Information
FDA approval date:
October 24, 2025
cytarabine
Rate Add review Rx D N
Generic name:
cytarabine systemic
Drug class:
antimetabolites
For consumers:
dosage, interactions, side effects
For professionals:
AHFS DI Monograph, Prescribing Information
Venclexta
Rate Add review Rx N
Generic name:
venetoclax systemic
Drug class:
miscellaneous antineoplastics
For consumers:
dosage, interactions, side effects
For professionals:
Prescribing Information
FDA approval date:
November 21, 2018
venetoclax
9.0 2 reviews for venetoclax to treat Acute Myeloid Leukemia Rx N
Generic name:
venetoclax systemic
Brand name:
Venclexta
Drug class:
miscellaneous antineoplastics
For consumers:
dosage, interactions, side effects
For professionals:
AHFS DI Monograph
Idhifa
Rate Add review Rx N
Generic name:
enasidenib systemic
Drug class:
miscellaneous antineoplastics
For consumers:
dosage, interactions, side effects
For professionals:
Prescribing Information
FDA approval date:
August 1, 2017
Tibsovo
Rate Add review Rx N
Generic name:
ivosidenib systemic
Drug class:
miscellaneous antineoplastics
For consumers:
dosage, interactions, side effects
For professionals:
Prescribing Information
FDA approval date:
July 20, 2018
azacitidine
8.0 1 review for azacitidine to treat Acute Myeloid Leukemia Rx D N
Generic name:
azacitidine systemic
Brand name:
Onureg
Drug class:
miscellaneous antineoplastics
For consumers:
dosage, interactions, side effects
For professionals:
AHFS DI Monograph, Prescribing Information
decitabine
Off-label
Rate Add review Rx D N
Generic name:
decitabine systemic
Drug class:
antimetabolites
For consumers:
dosage, interactions, side effects
For professionals:
AHFS DI Monograph, Prescribing Information
Off-label:
Yes
idarubicin
Rate Add review Rx D N
Generic name:
idarubicin systemic
Brand name:
Idamycin PFS
Drug class:
antibiotics/antineoplastics
For consumers:
dosage, interactions, side effects
For professionals:
AHFS DI Monograph, Prescribing Information
Xospata
8.0 1 review for Xospata to treat Acute Myeloid Leukemia Rx N
Generic name:
gilteritinib systemic
Drug class:
multikinase inhibitors
For consumers:
dosage, interactions, side effects
For professionals:
Prescribing Information
FDA approval date:
November 28, 2018
Rydapt
Rate Add review Rx N
Generic name:
midostaurin systemic
Drug class:
multikinase inhibitors
For consumers:
dosage, interactions, side effects
For professionals:
Prescribing Information
FDA approval date:
April 28, 2017
vincristine
Rate Add review Rx D N
Generic name:
vincristine systemic
Drug class:
mitotic inhibitors
For consumers:
dosage, interactions, side effects
For professionals:
AHFS DI Monograph, Prescribing Information
Onureg
Rate Add review Rx D N
Generic name:
azacitidine systemic
Drug class:
miscellaneous antineoplastics
For consumers:
dosage, interactions, side effects
For professionals:
Prescribing Information
FDA approval date:
September 1, 2020
daunorubicin
Rate Add review Rx D N
Generic name:
daunorubicin systemic
Drug class:
antibiotics/antineoplastics
For consumers:
dosage, interactions, side effects
For professionals:
AHFS DI Monograph, Prescribing Information
Mylotarg
1.5 2 reviews for Mylotarg to treat Acute Myeloid Leukemia Rx D N
Generic name:
gemtuzumab systemic
Drug class:
CD33 monoclonal antibodies
For consumers:
dosage, interactions, side effects
For professionals:
Prescribing Information
FDA approval date:
September 1, 2017
Vyxeos
Rate Add review Rx N
Generic name:
cytarabine liposomal / daunorubicin liposomal systemic
Drug class:
antineoplastic combinations
For consumers:
dosage, interactions, side effects
For professionals:
Prescribing Information
FDA approval date:
August 3, 2017
enasidenib
Rate Add review Rx N
Generic name:
enasidenib systemic
Brand name:
Idhifa
Drug class:
miscellaneous antineoplastics
For consumers:
dosage, interactions, side effects
For professionals:
AHFS DI Monograph
gilteritinib
8.0 1 review for gilteritinib to treat Acute Myeloid Leukemia Rx N
Generic name:
gilteritinib systemic
Brand name:
Xospata
Drug class:
multikinase inhibitors
For consumers:
dosage, interactions, side effects
For professionals:
AHFS DI Monograph
Daurismo
Rate Add review Rx N
Generic name:
glasdegib systemic
Drug class:
hedgehog pathway inhibitors
For consumers:
dosage, interactions, side effects
For professionals:
Prescribing Information
FDA approval date:
November 21, 2018
gemtuzumab
1.5 2 reviews for gemtuzumab to treat Acute Myeloid Leukemia Rx D N
Generic name:
gemtuzumab systemic
Brand name:
Mylotarg
Drug class:
CD33 monoclonal antibodies
For consumers:
dosage, interactions, side effects
For professionals:
AHFS DI Monograph
midostaurin
6.0 2 reviews for midostaurin to treat Acute Myeloid Leukemia Rx N
Generic name:
midostaurin systemic
Brand name:
Rydapt
Drug class:
multikinase inhibitors
For consumers:
dosage, interactions, side effects
For professionals:
AHFS DI Monograph
ivosidenib
Rate Add review Rx N
Generic name:
ivosidenib systemic
Brand name:
Tibsovo
Drug class:
miscellaneous antineoplastics
For consumers:
dosage, interactions, side effects
For professionals:
AHFS DI Monograph
cytarabine liposomal / daunorubicin liposomal
Rate Add review Rx N
Generic name:
cytarabine liposomal / daunorubicin liposomal systemic
Brand name:
Vyxeos
Drug class:
antineoplastic combinations
For consumers:
dosage, interactions, side effects
For professionals:
AHFS DI Monograph
glasdegib
Rate Add review Rx N
Generic name:
glasdegib systemic
Brand name:
Daurismo
Drug class:
hedgehog pathway inhibitors
For consumers:
dosage, interactions, side effects
For professionals:
AHFS DI Monograph

Frequently asked questions

View more FAQ

Topics under Acute Myeloid Leukemia

Learn more about Acute Myeloid Leukemia

Care guides

Symptoms and treatments

Legend

Rating For ratings, users were asked how effective they found the medicine while considering positive/adverse effects and ease of use (1 = not effective, 10 = most effective).
Activity Activity is based on recent site visitor activity relative to other medications in the list.
Rx Available for purchase by prescription only.
OTC Available for purchase over-the-counter.
Rx/OTC Available for purchase by prescription or over-the-counter.
Alcohol The medication interacts with alcohol (if marked with "✕").
New approval The FDA has approved this medication within the past year.
Off-label The FDA may not approve this medication for the treatment of this condition.
EUA An Emergency Use Authorization (EUA) allows the FDA to authorize unapproved medical products or unapproved uses of approved medical products to be used in a declared public health emergency when there are no adequate, approved, and available alternatives.
Expanded access Expanded access is a potential pathway for a patient with a serious or immediately life-threatening disease or condition to gain access to an investigational medical product (drug, biologic, or medical device) for treatment outside of clinical trials when no comparable or satisfactory alternative therapy options are available.
Pregnancy Category
A Adequate and well-controlled studies have failed to demonstrate a risk to the fetus in the first trimester of pregnancy (and there is no evidence of risk in later trimesters).
B Animal reproduction studies have failed to demonstrate a risk to the fetus and there are no adequate and well-controlled studies in pregnant women.
C Animal reproduction studies have shown an adverse effect on the fetus and there are no adequate and well-controlled studies in humans, but potential benefits may warrant use in pregnant women despite potential risks.
D There is positive evidence of human fetal risk based on adverse reaction data from investigational or marketing experience or studies in humans, but potential benefits may warrant use in pregnant women despite potential risks.
✕ Studies in animals or humans have demonstrated fetal abnormalities and/or there is positive evidence of human fetal risk based on adverse reaction data from investigational or marketing experience, and the risks involved in use in pregnant women clearly outweigh potential benefits.
N FDA has not classified the drug.
Controlled Substances Act (CSA) Schedule
M The drug has multiple schedules. The schedule may depend on the exact dosage form or strength of the medication.
U CSA Schedule is unknown.
N Is not subject to the Controlled Substances Act.
1 Has a high potential for abuse. Has no currently accepted medical use in treatment in the United States. There is a lack of accepted safety for use under medical supervision.
2 Has a high potential for abuse. Has a currently accepted medical use in treatment in the United States or a currently accepted medical use with severe restrictions. Abuse may lead to severe psychological or physical dependence.
3 Has a potential for abuse less than those in schedules 1 and 2. Has a currently accepted medical use in treatment in the United States. Abuse may lead to moderate or low physical dependence or high psychological dependence.
4 Has a low potential for abuse relative to those in schedule 3. It has a currently accepted medical use in treatment in the United States. Abuse may lead to limited physical dependence or psychological dependence relative to those in schedule 3.
5 Has a low potential for abuse relative to those in schedule 4. Has a currently accepted medical use in treatment in the United States. Abuse may lead to limited physical dependence or psychological dependence relative to those in schedule 4.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer